Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Mutational profile evaluates metastatic capacity of Chinese colorectal cancer patients, revealed by whole-exome sequencing
Genomics ( IF 4.4 ) Pub Date : 2024-03-16 , DOI: 10.1016/j.ygeno.2024.110809 Yian Yang , Jiawei Chen , Honghua Peng , Zhigang Xiao , Wei Xu , Mingchuan Zheng , Zheng Li , Peiguo Cao
Genomics ( IF 4.4 ) Pub Date : 2024-03-16 , DOI: 10.1016/j.ygeno.2024.110809 Yian Yang , Jiawei Chen , Honghua Peng , Zhigang Xiao , Wei Xu , Mingchuan Zheng , Zheng Li , Peiguo Cao
Colorectal cancer (CRC) is the third most common cancer and the prevalence rate of CRC is increasing in the China. In this study, whole-exome sequencing (WES) was performed on primary tissues of 47 CRC Chinese patients including 22 metastatic and 25 non-metastatic patients. By comparison with data from western colorectal cancer patients in the Cancer Genome Atlas (TCGA), we identified a number of genes that are more likely to be mutated in Chinese colorectal cancer patients, such as MUC12, MUC12, MUC2, MUC4, HYDIN and KMT2C. Interestingly, MUC family genes including MUC12, MUC2 and MUC4, have mutation rates of >20%, while the mutation frequency was extremely low in western colorectal cancer patients, which were <3% in TCGA and 0% in Memorial Sloan Kettering Cancer Center (MSKCC). We detected metastasis-specific mutated genes including TCF7L2, MST1L, HRNR and SMAD4, while MUC4, NEB, FLG and RFPL4A alteration is more prevalent in the non-metastasis group. Further analysis reveals mutation genes in metastasis group are more focus in the Wnt and Hippo signaling pathway. APC, SMAD4 and TCF7L2 accounted for the major genetic abnormalities in this pathway. In conclusion, this study identified the unique characteristics of gene mutations in Chinese patients with colorectal cancer, and is a valuable reference for personalized treatment in Chinese CRC patients.
更新日期：2024-03-16
京公网安备 11010802027423号